SCHEMBL370028

SCHEMBL370028

CCOC(=O)c1cn(Cc2ccc(OC)cc2)nc1C(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 2/20 0.53
MEN1 O00255 2/20 0.53
MAPT P10636 1/20 0.48
ALDH1A1 P00352 9/20 0.48
LMNA P02545 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
ELANE P08246 1/20 0.47
GLA P06280 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1052418 0.82 PDE4D (0.49) KMT2ANPC1MEN1MAPTALDH1A1
SCHEMBL2507139 0.81 AADAT (0.44) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL25191628 0.81 MAPT (0.47) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2507978 0.81 MAPT (0.47) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL369424 0.81 UCHL1 (0.47) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL3356514 0.80 MAPT (0.46) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2508034 0.80 MAPT (0.46) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL369164 0.80 ALDH1A1 (0.48) KMT2ANPC1MAPTALDH1A1LMNA
SCHEMBL27163231 0.80 ALDH1A1 (0.52) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL2512134 0.79 MAPT (0.47) KMT2ANPC1RAB9AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS BOLEA CHRISTELLE (CH) 2013-08-15 US disclosed
EP-2595986-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2013-05-29 EP disclosed
WO-2012009009-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM2, GRM4, GRM1 KMT2A 1336/4885NPC1 1289/4885RAB9A 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.